Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.305 AUD | +1.56% |
|
+1.16% | +0.38% |
Apr. 30 | Wilsons Upgrades Monash IVF to Overweight from Market-Weight, Price Target is AU$1.58 | MT |
Apr. 12 | RBC Capital Markets Starts Monash IVF Group at New Sector Perform, Price Target is AU$1.50 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.38% | 338M | C+ | ||
+17.30% | 82.59B | C+ | ||
-26.28% | 72.22B | B- | ||
-1.34% | 26.41B | C+ | ||
+4.17% | 17.69B | A- | ||
-9.26% | 16.89B | B | ||
+4.08% | 15.6B | A- | ||
+76.90% | 13.7B | C- | ||
+76.96% | 12.77B | C+ | ||
-25.96% | 12.76B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MVF Stock
- Ratings Monash IVF Group Limited